BTG
BTG Limited is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The current name was adopted when the British Technology Group changed its name on 27 May 1998. BTG was a constituent of the FTSE 250 Index until it was acquired by Boston Scientific in August 2019.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Cyanokit | Hydroxocobalamin | 2006-12-15 | ||
| Thyrosafe | Potassium iodide | 2002-09-10 | ||
| Voraxaze | Glucarpidase | 2012-01-17 | ||
| Vistogard | Uridine triacetate | 2015-12-11 | 2027 | |
| Xuriden | Uridine triacetate | 2015-09-04 | 2027 |
Clinical Trials
No data
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use